Pbx-regulating protein-1 (Prep1) is a tumor suppressor, whereas myeloid ecotropic viral integration site-1 (Meis1) is an oncogene. We show that, to perform these activities in mouse embryonic fibroblasts, both proteins competitively heterodimerize with pre-B-cell leukemia homeobox-1 (Pbx1). Meis1 alone transforms Prep1-deficient fibroblasts, whereas Prep1 overexpression inhibits Meis1 tumorigenicity. Pbx1 can, therefore, alternatively act as an oncogene or tumor suppressor. Prep1 posttranslationally controls the level of Meis1, decreasing its stability by sequestering Pbx1. The different levels of Meis1 and the presence of Prep1 are followed at the transcriptional level by the induction of specific transcriptional signatures. The decrease of Meis1 prevents Meis1 interaction with Ddx3x and Ddx5, which are essential for Meis1 tumorigenesis, and modifies the growth-promoting DNA binding landscape of Meis1 to the growth-controlling landscape of Prep1. Hence, the key feature of Prep1 tumor-inhibiting activity is the control of Meis1 stability.
Pbx-regulating protein-1 (Prep1) is a tumor suppressor, whereas myeloid ecotropic viral integration site-1 (Meis1) is an oncogene. We show that, to perform these activities in mouse embryonic fibroblasts, both proteins competitively heterodimerize with pre-B-cell leukemia homeobox-1 (Pbx1). Meis1 alone transforms Prep1-deficient fibroblasts, whereas Prep1 overexpression inhibits Meis1 tumorigenicity. Pbx1 can, therefore, alternatively act as an oncogene or tumor suppressor. Prep1 posttranslationally controls the level of Meis1, decreasing its stability by sequestering Pbx1. The different levels of Meis1 and the presence of Prep1 are followed at the transcriptional level by the induction of specific transcriptional signatures. The decrease of Meis1 prevents Meis1 interaction with Ddx3x and Ddx5, which are essential for Meis1 tumorigenesis, and modifies the growth-promoting DNA binding landscape of Meis1 to the growth-controlling landscape of Prep1. Hence, the key feature of Prep1 tumor-inhibiting activity is the control of Meis1 stability.
T wo highly related members of the three amino acid loop extension (TALE) family of transcription factors play opposing roles in tumorigenesis. Myeloid ecotropic viral integration site-1 (Meis1) and Pbx-regulating protein-1 (Prep1, also known as pKnox1) belong to the MEINOX (a contraction of Meis and Knox) subfamily of the TALE family of homeoproteins that also includes the PBC (Pbx class) proteins. They are characterized by an atypical homeodomain harboring a TALE between the first and the second α-helices. Meis1 and Prep1 share highly conserved sequences in the domain required for the interaction with Pbx (HR1-HR2) and the homeodomain (HD) (1, 2) . The Meis1-or Prep1-interacting domain in Pbx proteins is the PBC-A-PBC-B domain. These interactions can take place in both the absence and presence of DNA (3) , and in fact, they are required for the transport of the complexes to the nucleus (4) . In addition, they also regulate the stability of Pbx proteins (5) . Furthermore, Meis1/ Prep1-Pbx heterodimers form ternary complexes with anterior Hox proteins, modulating the specificity of Hox-dependent gene expression (6) (7) (8) .
Meis1 cooperates with HoxA9 in leukemogenesis (9) . Its overexpression accelerates the occurrence of HoxA9-induced acute myeloid leukemia (AML); moreover, MEIS1 is up-regulated in more than 80% of human AML and in acute lymphoid leukemia harboring mixed lineage leukemia (MLL) translocations (10, 11) . Finally, Meis1 overexpression is a rate-limiting factor for the development of MLL-induced leukemias (12) . In addition to leukemia, MEIS1 expression seems to be relevant in leiomyosarcomas (13) , ovarian and uterine cancers (14) , and neuroblastomas and medulloblastomas (15) . All these evidences indicate that Meis1 acts as an oncogene to create and/or maintain a cellular context required for tumor formation.
In contrast to Meis1, Prep1 exerts a tumor-suppressive function. Indeed, the rare homozygous hypomorphic Prep1 i/i mice that survive embryonic lethality (and express 2% Prep1 mRNA and 2-10% protein compared with WT) (16) as well as the heterozygous Prep1 i/+ mice show a tumor-prone phenotype and develop pretumoral lesions or solid tumors late in life (17) . In agreement with this phenotype, Prep1 haploinsufficiency accelerates Myc-driven lymphomagenesis in EμMyc mice. In fact, Prep1 overexpression not only does not accelerate the onset of HoxA9-induced leukemia but also slightly delays its occurrence (18) . Moreover, tissue microarray immunohistochemistry revealed that PREP1 is absent or underexpressed in more than 70% of human tumors (17) . In fact, in mouse and human cells in culture, Prep1 deficiency leads to genomic instability and accumulation of DNA damage, a condition that favors malignancy (19) .
In the present work, we have confronted the opposing roles of Meis1 and Prep1 in tumorigenesis. (i) Meis1, on its own, can transform mouse embryonic fibroblasts (MEFs) but only in the absence of Prep1 (confirming the tumor-suppressive function of Prep1); however, growth of the Meis1-transformed MEFs is inhibited by Prep1 reexpression. (ii) Both Meis1 oncogenic and Prep1 tumor-suppressive activities require pre-B-cell leukemia homeobox-1 (Pbx1). (iii) Prep1 controls Meis1a-transforming activity by controlling its level through a Pbx1-dependent posttranslational mechanisms. (iv) Prep1 inhibits Pbx1-dependent Meis1a interaction with Ddx3x and Ddx5, two RNA helicases essential for the proliferation of Meis1a-induced tumors. (v) In addition to competing for Pbx1, Prep1 also reduces the range of Meis1 target genes partially by competitive binding to the same genes when overexpressed. This alteration results in a shift of target genes from Meis1-dependent, avian erythroblastosis oncogene B (ERBB)-dependent growth stimulation to Prep1-dependent, cell cycle-controlling gene categories.
Results

Meis1 Transforms Prep1 i/i but Not Prep1
in primary WT MEFs, Meis1a overexpression had the same effect as Ras V12 (i.e., blocked growth, possibly inducing oncogeneinduced senescence) (Fig. S1C) . However, Meis1a overexpression in the same WT MEFs induced cell growth when coinfected with another oncogene (i.e., Ras V12 or Myc) (Fig. S1C ), a feature expected for an oncogene (20) . It must be noticed that Meis1 transforms primary hematopoietic progenitors only in collaboration with HoxA9 (18).
In p53 −/− primary MEFs, in fact, Meis1a induced cell growth on its own (Fig. S1D) . Surprisingly, in immortalized p53 +/+ but Prep1 i/i MEFs, overexpression of Meis1a robustly increased cell number (Fig. S1E) . We conclude, therefore, that induction of cell growth is a property of overexpressed Meis1a but that this effect is evident only in the absence of p53 or Prep1.
We have used MEFs to measure Meis1a-dependent oncogenic transformation, looking for the loss of contact inhibition in monolayer, growth of cellular foci, and anchorage-independent growth in soft agar (21, 22) .
Primary WT MEFs are not transformed by a single oncogene (20) , and in fact, Meis1 or Ras V12 did not transform primary MEFs (Fig. S1C) is no longer required, allowing efficient transformation by Meis1 alone. In addition, the soft agar colonies formed by Prep1 i/i cells were bigger than those formed by Prep1 +/+ cells (Fig. 1B) . The higher transforming activity of Meis1 in Prep1 i/i cells agrees with the absence of the tumor-suppressive activity of Prep1. We also tested PREP1 tumor-suppressive function in the human neuroblastoma cell line IMR32. We screened a panel of eight different human brain tumor cell lines and selected the IMR32 cell line, which has the highest MEIS1 expression level (Fig. S3A) , because in these cells, MEIS1 is amplified (23) . We either overexpressed or down-regulated PREP1 in these cells using a specific vector or shRNA, respectively (Fig. S3B) . As shown in Fig. S3C , PREP1 overexpression decreased, whereas its down-regulation increased the growth rate of IMR32 cells. Moreover, PREP1 level modulated the foci formation capacity and soft agar growth of the cells (Fig. S3 D and E) . The number of foci in PREP1-overexpressing cells decreased, whereas it increased in PREP1 down-regulated cells (Fig. S3D ). In agreement with these data, the number and the size of the soft agar colonies decreased on PREP1 overexpression and increased on PREP1 knockdown (Fig. S3E) . These data provide additional support for the tumor-suppressive function of PREP1 in tumor cells overexpressing MEIS1.
We then analyzed the effect of restoring Prep1 level in Prep1
MEFs. Colony formation in soft agar was significantly inhibited by Prep1 reexpression (Fig. 1B) .
To definitively confirm the differential effect of Meis1 and Prep1 in tumorigenesis, we have tested the in vivo growth of the various cell lines by injecting them into immunodeficient nu/nu mice. First, s.c. transplantation of the infected cells revealed that only Prep1 i/i (and not Prep1 +/+ ) Meis1a-overexpressing cells formed tumors in mice within the time frame of the experiment (Fig. 1C) . Second, Prep1 +/+ cells required at least two oncogenes (Meis1 and HoxA9) for the tumorigenesis (Fig. 1C) . Third, Prep1 reexpression remarkably decreased tumor growth rate of the Prep1
Meis1a-transformed cells (Fig. 1C) . Histopathological examination of sections showed sarcoma-like tumors, with no major differences between the two genotypes (Fig. 1D) . We conclude that Meis1a fully transforms MEFs but only in the absence of Prep1 and that Prep1 can inhibit the growth of Meis1a-dependent tumors.
Reexpression of Prep1 in Meis1a-Overexpressing Prep1 i/i Cells Decreases Meis1a Stability. Prep1 i/i MEFs essentially express very low level of Meis1a ( Fig. 2A ) and no Prep1 (16) . However, they robustly expressed the transduced FLAG-Meis1a. On Prep1 reexpression, the level of the transduced FLAG-Meis1a decreased ( Fig. 2A) . This data suggests that Prep1 affects Meis1a level by a posttranscriptional mechanism, because transduced Meis1a is expressed under a heterologous promoter. Indeed, the level of Meis1a is decreased by Prep1 overexpression when tested with both anti-FLAG and anti-Meis1 antibodies ( Fig. 2A) . Additionally, in fact, the decrease of Meis1a did not depend on a decrease of the level of its mRNA (Fig. 2B) , confirming that Prep1 acts through a posttranscriptional mechanism. The observation was not limited to the MEFs because also PREP1 overexpression in IMR32 cells decreased the endogenous MEIS1A level (Fig. S4) .
We have tested the stability of Meis1a in Prep1-overexpressing cells using the proteasome inhibitor MG132 and the protein translation inhibitor cycloheximide (CHX). In the presence of MG132, the level of Meis1a in Prep1 i/i cells overexpressing Meis1a-Prep1 increased with the time (Fig. 2C) , indicating that Meis1a undergoes proteasomal degradation. Treatment of the Meis1a and Meis1a-Prep1 transduced Prep1 i/i cells with CHX allowed us to compare the extent of degradation of Meis1a in the absence and the presence of Prep1. In the presence of Prep1, the steady state level of Meis1a decreased about fourfold ( Fig. 2A) because of at least a threefold faster degradation rate, which was shown in the presence of CHX (Fig. 2D ).
Pbx-Interacting Domain of Prep1 Is Required to Inhibit the Growth of Meis1a-Transformed MEFs. Pbx is the most frequent interactor of Prep1 at the genomic level in mouse embryos (24) . We, therefore, explored whether the Pbx-interacting region (HR1-HR2) of Prep1 or its other domains were required for the tumor growth. Different FLAG-Prep1 deletion mutants were constructed and are outlined in Fig. 3A .
The expression of each mutant was evaluated by semiquantitative RT-PCR (Fig. 3B) and immunoblotting (Fig. 3C ) by infecting passage-35 Prep1 i/i MEFs. Full-length and mutated proteins of the predicted molecular weight were observed by immunoblotting with an anti-FLAG antibody (Fig. 3C) . Because the nuclear localization of Prep1 depends on the interaction with Pbx (4), the subcellular localization of the different mutant proteins was also tested by immunoblotting of nuclear and cytoplasmic extracts. Both Prep1ΔHD and Prep1Δ carboxy terminal domain (CTD) mutants were localized in the nucleus (Fig.  3C) . Immunofluorescence assays confirmed these results (Fig.  S5 ). The nuclear localization of the ΔHD and ΔCTD mutants indicates that the mutants are correctly folded, interact with Pbx, and are transported to the nucleus. Prep1ΔHR1+2 mutant was found in both the nucleus and the cytoplasm. In addition, we also tested the interaction of the mutant proteins with Pbx using anti-FLAG immunoprecipitation and Pbx1a, Pbx1b, and Pbx2 immunoblotting. In all cases, except with Prep1ΔHR1+2, the proteins coimmunoprecipitated Pbx. As expected, Prep1ΔHR1+2 did not interact (Fig. 3D) . Thus, the partial presence of the ΔHR1+2 mutant in the nucleus, despite its inability to interact with Pbx, may suggest that additional mechanisms apart from the Pbx interaction can be involved in Prep1 nuclear localization.
It has been shown that Prep1 i/i MEFs display an increased basal level of apoptosis and higher sensitivity to UV irradiation compared with WT (25) . Moreover, Prep1 overexpression increases the sensitivity of the cells to genotoxic stress (26) . Thus, we tested the effect of Meis1 and Prep1 mutants' coexpression on the basal level of apoptosis in Prep1 i/i MEFs. As shown in Fig. S6 , cells overexpressing Meis1a-Prep1 or Meis1a-Prep1ΔC displayed a low-level increase of basal apoptosis compared with empty vector-transduced cells. Overexpression of Meis1a alone or together with other Prep1 derivatives had a lower effect. Thus, the marginal effect of Prep1 overexpression on apoptosis may have minimally affected the growth of the various cells.
To test the ability of the different Prep1 mutants to substitute for Prep1 in inhibiting the growth of Meis1a-transformed MEFs, passage-35 Prep1 i/i MEFs overexpressing FLAG-Meis1a were retrovirally infected with different FLAG-Prep1 mutants. The expression of exogenous Meis1a and Prep1 mutants was checked by Western blotting with an anti-FLAG antibody (Fig. 3E ). The decrease of FLAG-Meis1a was observed not only for the fulllength protein but also for its mutants, with the exception of Prep1ΔHR1+2. The ability of ΔHD and ΔCTD mutants to interact with Pbx (see above) suggests that the Prep1-dependent Meis1a degradation relies on the formation of a Prep1-Pbx complex. Meis1a-transformed Prep1 i/i MEFs infected with full-length or the above Prep1 mutants' retroviruses were subjected to anchorage-independent growth assays in soft agar. Full-length Prep1, Prep1ΔHD, and Prep1ΔCTD significantly reduced the number of soft agar colonies. The effect of full-length Prep1 was a threefold decrease, whereas the mutants showed a twofold effect. However, Prep1ΔHR1+2 showed no inhibitory effect (Fig. 3F) . When the cells were injected in nu/nu mice, Prep1ΔHD and ΔCTD mutants still inhibited in vivo growth of Meis1a-transformed cells, unlike the Prep1ΔHR1+2 mutant that had no effect (Fig. 3G) . These results indicate that the HR1+2 domain significantly contributes to Prep1 tumor-suppressive function, suggesting that the tumorsuppressive function is exerted by a Prep1-Pbx1 complex.
Both Growth of Meis1a-Transformed Prep1 i/i MEFs and Its Inhibition by Prep1 Require Pbx1. Both Meis1 and Prep1 interact with Pbx1 and Pbx2 through the conserved HR1+HR2 surface (4) and increase its stability (Fig. S7A ). Prep1 i/i MEFs overexpressing Meis1a or Meis1a-Prep1 were depleted of Pbx1 by one of two different specific shRNAs, resulting in 80-90% reduction of Pbx1 protein level. A control shRNA had no effect (Fig. 4A ). Cells downregulated for Pbx1 are, henceforth, indicated as Pbx1 kd .
Pbx1
kd cells displayed a decreased Meis1a protein level ( Fig.  4B ) but no decrease of Meis1 mRNA (Fig. 4C) . Moreover, overexpression of tandem affinity purification (TAP) -Pbx1b in these cells sharply increased the Meis1a level (Fig. S7B ). This data suggests that Meis1 is more stable in MEFs when they overexpress Pbx, possibly because Meis1 is in complex with Pbx1. To exclude the possibility that Meis1a level reduction was caused by its relocation, we checked the Meis1a level in nuclear and cytoplasmic extracts of Pbx1 kd cells overexpressing Meis1a. As shown in Fig. S7C , in Pbx1 kd cells Meis1a reduction was not caused by relocation, because there was no Meis1a in the cytoplasmic extract of these cells. Pbx1 down-regulation had no effect on Prep1 level in Prep1-overexpressed cells (Fig. S7D) .
Pbx1 kd -Meis1a-transformed cells proliferated almost as efficiently as the scrambled shRNA control cells (Fig. S7E ). We also tested the effect of Pbx1 depletion on the basal level of apoptosis of Meis1a-transformed cells. As shown in Fig. S7F , down-regulation of Pbx1 did not induce apoptosis in the cells. However, it marginally decreased the apoptotic rate of these cells. We conclude that Pbx1 down-regulation does not affect either cell growth or apoptosis in this system. However, soft agar assays showed that the colony formation potential of Pbx1 kd -Meis1a-transformed cells was substantially decreased (>69%) compared with the scrambled shRNA vector (Fig. 4D ). In addition, nu/nu mice transplanted with Pbx1 kd -Meis1a-transformed cells yielded smaller and slowergrowing tumors compared with the control group (Fig. 4E ). These effects were not observed in cells also overexpressing Prep1 (their tumorigenic activity was already lower) ( Fig. 4 D and F) , and in fact, in the absence of Pbx1, Prep1 showed no tumor-suppressive effect. Data in Fig. 4 E and F were part of the same experiment and are presented separately for the sake of clarity.
The fact that Meis1a does not transform Pbx1 kd cells as efficiently as control indicates that Meis1a-mediated transformation is dependent on the presence of Pbx1 and further supports the idea that, not only in MLL-induced leukemia (12) but also in MEFs transformation, Meis1a functions in complex with Pbx. Likewise, the lack of the inhibitory effect of Prep1 on Pbx1 kdMeis1a-transformed cells shows that Prep1 inhibition of the Meis1a-induced transformation requires Pbx1. All these data suggest that Meis1a and Prep1 compete for Pbx1 and hence, that Pbx1 cooperates with an oncogene (Meis1) as well as a tumor suppressor (Prep1), confirming the previous data with Prep1ΔHR1 +2 mutant (Fig. 3) .
We conclude that Pbx1 plays an important role in both Meis1 tumorigenic and Prep1 tumor-suppressive activities, becoming a previously unidentified example of a single protein that can affect tumorigenesis in both directions. The underlying mechanism is, however, different from that mechanism of the Myc/ Mad/Max system (Discussion).
Prep1 Competition for Pbx1b Binding Impairs Meis1a Interaction with
Ddx RNA Helicases. We directly tested competition between Prep1 and Meis1a for Pbx1b binding. We expressed GST-Prep1, Meis1, and Pbx1b in Escherichia coli and purified these proteins from bacterial lysate (Fig. 5A ). Prep1 and Meis1a were cleaved from the GST-tag with PreScission protease, whereas GST-Pbx1b was used as bait in a pull-down assay with the purified, soluble Prep1 and Meis1a. GST was used as a negative control. As shown in Fig. 5B , a major Meis1a binding reduction was observed in the presence of a 10-fold excess of Prep1. Although not really quantitative, these results show that Prep1 competes with Meis1a to bind Pbx1b.
To gain insight into the molecular mechanisms of Meis1a oncogenic activity and its inhibition by Prep1, we analyzed the Meis1a interactome using TAP (22) in the absence or the presence of overexpressed Prep1. We introduced a TAP-Meis1a (Materials and Methods) expression vector in Prep1 i/i cells (Prep1 i/i TAPMeis1a) or Prep1 i/i cells reexpressing Prep1 (Prep1 i/i TAP-Meis1a-Prep1). The TAP-purified proteins were run on SDS-PAGE and identified by MS. Fig. 5C shows all of the identified proteins with their exponentially modified protein abundance index and Mascot score. This analysis showed that Meis1a copurified with Pbx1 and Pbx2, which was expected. Moreover, Meis1a also copurified with Mybbp1a, a protein that has also been shown to interact with Prep1 through the HR1 domain (27, 28) . No Prep1 peptides were identified in the analysis, confirming that Meis1a and Prep1 do not form a complex. Importantly, we also identified additional proteins that copurify only in the absence of Prep1 (Fig. 5C ), particularly the two ATP-dependent RNA helicases Ddx3x and Ddx5. Using the anti-FLAG antibody, we confirmed that Ddx3x and Ddx5 coprecipitated with Meis1 and not Prep1-specific antibodies (Fig. 5 D and E) . Moreover, Meis1a did not coprecipitated with Prep1 antibody (Fig. 5E) . To explain the impairment of the Ddx3x and Ddx5 interactions with Meis1a in the presence of Prep1, we checked whether Pbx1, the common interactor of Prep1 and Meis1a, is required for Ddx interaction with Meis1a, because Prep1 and Meis1a compete for Pbx1 binding (detailed above). Indeed, the Meis1a-Ddx coimmunoprecipitation disappeared in cells in which Pbx1 has been down-regulated with a specific shRNA (Fig. 5F ). Thus, Pbx1 is required for Meis1a interaction with Ddx proteins.
Ddx3x and Ddx5 Depletion Impairs Cell Growth and Colony Formation in Soft Agar. Ddx3 and Ddx5 are involved and required for tumorigenicity (29, 30) . Indeed, depletion of Ddx3x and Ddx5 protein levels by ∼50% and ∼70%, respectively, using two independent shRNAs specifically targeting each gene (Fig. 6A) (Fig. S8) but changed the morphology of Meis1a-overexpressing Prep1 i/i cells (but not control cells). The cells became abnormally flat, looking like serum-starved cells, and several round bodies appeared, possibly corresponding to cell carcasses (Fig. 6B) . As expected (23, 31) , Ddx down-regulation severely compromised the growth of Meis1a-transduced Prep1 i/i cells (Fig. 6C) . Ddx depletion also strongly reduced the Meis1a-dependent anchorage-independent growth in semisolid medium (Fig. 6D) . Overall, these results indicate that both Ddx3x and Ddx5 have important roles in cell growth, and their down-regulation inhibits Meis1a-induced transformation in vitro. Overlap of these data shows that the reduction of the Meis1 binding gene caused by Prep1 was totally at the expense of those extra peaks bound under conditions of Meis1a overexpression (Fig. 7A) but not the sites bound by Meis1 in the parental cells (EV sample).
In addition, in MP cells overexpression of Prep1 prevented the binding of Meis1 to 3,590 genes, which were otherwise bound in the M cells; of these genes, 1,465 (40.8%) were directly occupied by Prep1, whereas the remaining 2,125 genes (59.2%) were not bound by either Prep1 or Meis1 in the MP cells (Fig. 7B ). The 1,465 genes must include those genes that affect Meis1 oncogenic activity, and we have called them the tumor-inhibiting signature. However, 3,590 genes bound by Meis1 in the M cells must include those genes that mediate Meis1 tumorigenicity and hence, are called the tumor-promoting signature.
Gene Ontology (GO) analysis (Fig. 7C) , showed that the tumorpromoting signature was uniquely enriched in tumor-linked categories, like the regulation of the ERBB pathway, the regulation of centrosome cycle, and peptidyl-serine phosphorylation, whereas the tumor-inhibiting signature was uniquely enriched for categories like the negative regulation of the cell cycle, which are easily recognizable as tumor-suppressing. In addition, Prep1 also competed with Meis1 for regulating different cellular processes, such as protein tyrosine kinase activity and regulation of cell cycle.
Discussion
Here, we show that Prep1 and Meis1a compete for Pbx1 to prevent and induce tumorigenesis, respectively, highlighting the unique feature of Pbx1 that assumes a tumor suppressor or oncogenic role, depending on the transcriptional partner. We also highlight that the oncogenic-nononcogenic choice depends on the relative levels of Meis1a and Prep1, which in turn, depend on the extent and nature of the interactions with the common partner Pbx1. In the presence of excess Prep1, Pbx1 is squelched, and Meis1a is destabilized. This change tips the balance against tumorigenesis. Other levels of competition have been unraveled, in which Prep1 prevents binding of Meis1 to genes only bound by the ectopic conditions without affecting those genes bound at the endogenous level.
This feature is not MEF-or mouse-specific; also, the human IMR32 neuroblastoma cell line is transformed by MEIS1 gene amplification (32) , and in these cells, the decrease of MEIS1A induced by PREP1 modulates the tumorigenic potential (Fig. S3) .
Two sets of data may seem to decrease the novelty of these findings. First, the Prep/Pbx/Meis system is reminiscent of the Myc/Max/Mad network, in which Max can act as an oncogene when bound to Myc or inhibit tumorigenesis when bound to Mad. However, in this case, a major role is played by the transactivation domain of Myc and Mad and not by the control of proteins stability (33) . Second, the Meis1 CTD is required for HoxA9 cooperation in leukemogenesis (18, 34, 35) . However, swapping the Prep1 with the Meis1 CTD has failed to convert Prep1 into an HoxA9-cooperating oncogene (36) , which succeeds, however, when a full-length Prep1 is lengthened with the Meis1-CTD that induces Meis1-specific gene sets (36) . However, these data do not prove that the central mechanism is transcriptional, because no studies of protein levels were carried out and there is peculiarity of the Prep1-Meis1 chimeric protein carrying both CTDs. Other than the difference of the cellular system studied (hematopoietic cells vs. fibroblasts), in the present study, Meis1 transforms Prep1 i/i fibroblasts without a cooperating HoxA9 oncogene.
We show that Meis1 can act as a bona fide oncogene in fibroblasts and that its oncogenic capacity is strongly attenuated by its paralog Prep1. Therefore, Meis1 does not only function as an HoxA9-collaborating oncogene in leukemia (18) but also, may have independent activities in different tumor types.
Transformation of primary rodent fibroblasts requires at least two oncogenes or one oncogene in the absence of a tumor suppressor gene (20, 37) . Accordingly, Meis1 alone transforms primary p53 −/− MEFs but requires Ras V12 or Myc to transform WT cells (Fig. S1 C and D) S1 C and D) . Hence, the lack of either p53 or Prep1 tumor suppressors favors Meis1-dependent tumorigenesis but in different ways.
The inhibiting effect of Prep1 reexpression (Fig. 1C ) allows investigating the mechanisms involved in the tumor-suppressive function of Prep1 as well as the oncogenic activity of Meis1. Previous data (4) show that Prep1 controls the stability of Pbx1. In addition, we now show that the absence of Prep1 induces a concurrent Pbx1 decrease by a posttranscriptional mechanism (Fig. S7A) . However, Prep1 overexpression reduces Meis1a, again by a posttranscriptional protein degradation mechanism (Fig. 2) . Because both Prep1 and Meis1a form stoichiometric complexes with Pbx1, overall, the data indicate that Prep1 stabilizes Pbx1, whereas Pbx1 stabilizes Meis1a. Possibly, only the dimeric forms of Meis1a are stable. Therefore, under conditions of low Pbx1 or when Pbx1 is squelched by excess Prep1, Meis1a is reduced. Fig. 8 details these concepts in a schematic form. (i) Prep1 and Meis1a compete with each other for binding Pbx1 (Fig. 5B) and form a dimeric complex. (ii) By squelching Pbx1, excess Prep1 reduces the level of Meis1a protein (not mRNA), which acquires a shorter proteasome-dependent half-life. Conversely, Meis1a level increases in the absence of Prep1. These effects act not only at the level of the endogenously encoded protein but also, on the ectopically expressed protein. (iii) Pbx1 knockdown also reduces Meis1a level. Hence, overexpression or absence of any of the three proteins determines the presence, nature, and amount of the formed dimer. (iv) Thus, Meis1a stability, which is Prep1-and Pbx1-dependent, determines Meis1a level and the extent of tumor formation. (v) The level of Meis1a-Pbx1 complexes determines the extent of interaction with specific tumorigenic partners (i.e., the newly identified Ddx3x and Ddx5) as well as the regulation of an Meis1-specific set of tumor-promoting genes.
Pbx1, therefore, is central in both Meis1 tumorigenic and Prep1 tumor-suppressive functions. Although the Pbx1-Meis1a complex induces tumorigenesis, Pbx1-Prep1 complexes prevent it. Thus, Pbx1 becomes an oncogene or a tumor suppressor in Meis1-dependent tumorigenesis, depending on the choice of its transcriptional partner. Prep1 posttranscriptionally determines the level of expression of Meis1a, hence determining the fate of the cells. Prep1-dependent posttranscriptional regulation of Meis1a is, therefore, central in the choice of the tumor cell fate.
In the scheme in Fig. 8 , the tumorigenic decision depends only on the level of Meis1a. However, several data indicate a high degree of complexity. For example, Prep1 overexpression changes dramatically the genomic landscape of potential Meis1-regulated genes (Fig. 7) . For instance, Prep1 overexpression counteracts the targets of overexpressed Meis1 but does not affect the basic Meis1 targets. Prep1 reprogramming of Meis1-overexpressing cells cancels specific target gene sets that favor tumorigenesis, like the ERBB signaling pathway, while identifying others that control tumor cell proliferation (like regulation of the cell cycle) (Fig. 7C) .
In this work, we also identify two novel Meis1a interactors, the Ddx3x and Ddx5 RNA helicases (Fig. 5 C-F) . Ddx3x and Ddx5 specifically interact with Meis1a and not Prep1. Therefore, the inhibition of these interactions by Prep1 is not through competition but possibly caused by the decrease of Meis1a induced by Prep1 overexpression. The interaction requires Pbx1 and in fact, disappears when Pbx1 is down-regulated (Fig. 5F ). The disappearance of the Meis1a-Ddx interaction correlates well with the loss of tumorigenic activity in cells in which Prep1 is also overexpressed. Prep1 may dissociate Ddx3x and Ddx5 from the Pbx1-Meis1a complex by squelching Pbx1.
The interaction with the RNA helicases seems to be important for Meis1a tumorigenesis. Indeed, down-regulation of Ddx3x or Ddx5 inhibits the growth of the Meis1a-overexpressing cells and blocks soft agar colonies formation, which is in agreement with literature data causally connecting the helicases to neoplastic transformation (27, 28) , transcription, and cell cycle regulation (23, 38) . In fact, Ddx helicases interact with different transcription factors and act as transcriptional coactivators/corepressors (38) (39) (40) (41) (42) . Thus, Meis1a might recruit Ddx3x and Ddx5 to the regulatory regions of its target genes or sequester them, preventing the interaction with other genes.
The ability of Meis1 to interact with Pbx proteins is essential for the induction and maintenance of MLL-mediated myeloid transformation (12) . In this system, both the deletion of the HR1+2 domain of Meis1 (35) and the depletion of Pbx1 (12) abolish Meis1 oncogenic activity. Defining the function of different domains of a protein provides mechanistic insights. However, such information is missing for the tumor-suppressive functions of Prep1. In fact, the HR1+2 domain of Prep1 is indispensable for its tumorsuppressive function (Fig. 3 F and G) . Deletion of the HR1+2 domain prevented Prep1 inhibition of Meis1-induced anchorage-independent cell growth and tumor formation. However, Prep1ΔHD and Prep1ΔC mutants still sustain Pbx1 interaction and inhibit Meis1-induced tumorigenesis. The requirement for the HR1+2 domain indicates that the inhibitory form of Prep1 is the Prep1-Pbx1 complex.
Meis1a stability may be a pharmacological target in tumors. Because the Prep1 HR1+2 domain is not only required to both squelch Pbx1 and induce Meis1a instability (Fig. 3D) , it might be useful to reduce Meis1a level and tumorigenesis. In fact, protein domain or drugs able to interfere with the formation of a Pbx1-Meis1a complex, like recombinant HR1+2 domain from both Prep1 and Meis1a, may become possible drugs. Whether Meis1a HD and C-terminal domains might be useful in blocking Meis1-depending tumorigenesis by interfering with the Ddx interactions remains to be established. Attempts to synthesize PBX-DNAinhibiting drugs have been published (43) .
Because MEIS1 is implicated in neuroblastoma (15) , our data in IMR32 cells can suggest a potential therapeutic role for MEIS1 and PREP1 in this malignancy. Indeed, MEIS1 tumorigenicity is partially rescued by PREP1 reexpression, which, therefore, can partially revert the tumorigenicity. The effect of PREP1 reexpression might be important for future therapeutic developments, because many human tumors express very low levels of PREP1 (17).
Pbx1 is not the unique partner of Prep1 and Meis1. However, Prep1 is the most frequent interactor of Pbx1 in DNA binding in mouse embryos, and the Prep1-Pbx complexes account for a very large percentage of Prep1 binding sites in vivo. However, Meis1 is a less frequent partner of Pbx1 in the mouse embryo (about one-third as frequent) (24) . However, our in vivo data show that, in MEFs, Meis1 requires Pbx1 for oncogenic transformation. Indeed, Pbx1 depletion in Prep1 i/i cells overexpressing Meis1 attenuates their tumorigenic potential as assayed by soft agar colonies and size of tumors in transplanted mice (Fig. 4E) . Moreover, Prep1 is unable to rescue the residual Meis1-induced tumorigenicity in the Pbx1 down-regulated cells. In fact, cells coexpressing Meis1a and Prep1 show the same tumorigenic potential in Pbx1-depleted and control cells (Fig. 4F) , further supporting the idea that Prep1 tumor-suppressive function requires Pbx1. Thus, Pbx1 becomes a previously unidentified example of a molecule that modulates tumorigenesis in both directions based on whether it interacts with the Meis1 oncogene or the Prep1 tumor suppressor.
ChIP-seq data have highlighted an interesting relationship between Prep1 and Meis1 binding sites. On overexpression, Meis1 binds to a larger number of binding sites than in nonoverexpressing cells. However, this feature is counteracted by the concurrent overexpression of Prep1 (Fig. 7A) . In fact, Prep1 overexpression alters the genomic binding pattern of Meis1 by strongly decreasing the set of sites bound when it is overexpressed without affecting those sites bound in parental, nonoverexpressing cells. A fraction of these genes is bound by Prep1, whereas the rest remains unbound. This alteration is probably caused by the decrease of Meis1 in Prep1-overexpressing cells. These data would argue that Meis1 and Prep1 have common binding sites, which can be competitively bound. This concept will require deeper analysis.
In conclusion, we have presented evidence for a complex mechanism of tumorigenesis by members of the TALE family of transcription factors. Our data show that both Meis1 oncogenic and Prep1 tumor-suppressing activities depend on Pbx1 and hence, that Pbx1 is in the unique position to be both an oncogene and a tumor suppressor. Moreover, we confirm the tumor-suppressive function of Prep1 and show that the Meis1-dependent tumorigenicity is exerted and regulated primarily at the level of the Prep1-mediated stability of the oncogene. However, Prep1 can also use a broad range of mechanisms to suppress Meis1 oncogenicity from competition for Pbx1, which regulates Meis1a protein level and its interaction with Ddx, to limiting the range of Meis1 target genes and possibly, their deregulation.
Materials and Methods
Mice. Prep1
i/i mice have been described (16 , and 9 h with 10 μg/mL CHX at 37°C. Cells were lysed at the end of indicated time points, and total extracts were processed for immunoblotting.
Coimmunoprecipitation. Preparation of nuclear and cytoplasmic protein extract was performed as described (28); 300 μg nuclear lysate was immunoprecipitated using M2 anti-FLAG magnetic beads (Sigma-Aldrich) following the manufacture's protocol. Nuclear lysate from cells infected with EV was used as a negative control.
ChIP-seq and Data Analysis. ChIP-seq on the various MEF lines was performed and analyzed using standard protocols (24) . We used anti-Prep1 antibody and anti-Meis1/2 antibodies from Santa Cruz. ChIP DNA was sequenced on Illumina HiSeq 2000G. Single-end 50-bp reads were mapped with BWA software against the mm9 version of the mouse genome. The alignments were then used for peak calling. The data shown were obtained by selecting peaks with a P value < 10 −6 and a false discovery rate < 0.5%. Venn diagrams were generated using BioVenn software (44) . The original data have been deposited in the National Center for Biotechnology Information's GEO database and are accessible under accession no. GSE54221.
GO Analysis. GO term analysis was done with GOrilla, comparing the lists of genes with Prep1 or Meis1 binding sites against the list of all nuclear genes in Ensembl v63, with a P value cutoff of 10 −3 .
Statistical Analysis. All values are expressed as mean ± SD. Statistical analyses were done by two-tailed Student t test, unless differently specified.
Pull-Down Assay. Details of plasmid construction and pull-down assay are described in SI Materials and Methods.
TAP and MS Analysis. Details of plasmid construction, TAP purification, and MS analysis are provided in SI Materials and Methods. SI Materials and Methods describes in detail antibodies, shRNAs, plasmids, infections, cell growth, and apoptosis assays. Gene expression analysis is also described in SI Materials and Methods.
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Dardaei et al. 10 .1073/pnas.1321200111 SI Materials and Methods Antibodies. Pbx-regulating protein-1 (Prep1), pre-B-cell leukemia homeobox-1 (Pbx1), and Pbx2 antibodies were purchased from Santa Cruz Biotechnology. Myeloid ecotropic viral integration site-1 (Meis1) antibody was provided by Miguel Torres (Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain). Ddx5 and proliferating cell nuclear antigen were from Abcam. Ddx3x was from Millipore. FLAG clone M2, Vinculin, and Nucleolin were from Sigma-Aldrich, Novus Biologicals, and Novus Biologicals, respectively.
shRNAs. Sequence-verified MISSION shRNA lentiviral plasmids (Sigma-Aldrich) were used to down-regulate Ddx3x (TRCN0000103750 and TRCN0000103751), Ddx5 (TRCN000071103 and TRCN000071104), and Pbx1 (TRCN0000012575-#1 and TRCN0000012577-#2). shRNA targeting PREP1 has already been described (1).
Plasmids and Retroviral Infection. pMSCV-puro-Meis1a was obtained by cloning FLAG-tagged Meis1a cDNA into BglII/XhoI restriction sites of pMSCV-puro retroviral vector. Prep1 deletion mutants have been described (2) . The mutants were amplified from the original vectors and subcloned into the XhoI restriction site of pMSCV-hygro vector along with an FLAG-tag. pBabehygro-Ras v12 , pBabe-puro-Myc, and corresponding empty vectors were used. For retroviral transduction of mouse embryonic fibroblasts (MEFs) and IMR32, Phoenix-Eco and PhoenixAmpho cell lines were used, respectively.
Cell Growth Assay. Indicated numbers of cells were seeded into six-well culture plates in triplicate, and the medium was replaced every day. Depending on the experiment, at the indicated time points, cells were either counted directly with a FastRead 102 disposable counting chamber (Immune Systems) or fixed and stained with crystal violet; the absorbance of the cells was read at 595 nm.
Apoptosis Assay. The number of apoptotic cells was determined using propidium iodide staining and flow cytometry as described (3) . Briefly, 1 × 10 6 cells were fixed in 70% (vol/vol) cold ethanol and suspended in 1 mL staining solution containing 50 μg/mL propidium iodide (Sigma-Aldrich) and 250 μg/mL RNase (Invitrogen) for 3 h at room temperature. Stained cells were analyzed by FACSCalibur (BD Bioscience). Cells having a level of DNA below that level of G1 phase were considered apoptotic.
Gene Expression Analysis. RNeasy mini kit (QIAGEN) was used to perform all RNA extractions, and genomic DNA was degraded with RNase-free DNaseI (New England Biolabs); 1 μg total RNA was retrotranscribed in buffer containing dNTPs, RNase OUT, random primers, and superscript III reverse transcriptase (Invitrogen). Semiquantitative PCR was carried out on the GeneAmp PCR system a700 (Life Technologies) using the following primers: forward primer, 5′-ATGATGGCTACACAGACATTAAG-3′ and reverse primer, 5′-CTACTGCAGGGAGTCACTGTTC-3′. For Prep1Δ carboxy terminal domain, the following reverse primer was used: 5′-TTACATTGGCTGAAGAATTGGTC-3′.
Quantitative real-time PCR was performed using SYBR Green PCR Master Mix on a Roche Light Cycler 480 using specific Meis1 primers (4). GAPDH was used as control to normalize the results (1) . For all experiments, reverse transcriptase minus controls was performed.
Pull-Down Assay. Meis1a and Pbx1b fragments were amplified from the cDNA pool prepared from MEFs using the following primers.
Meis1a: Forward, 5′-ATGGCGCAAAGGTACGACGAC-3′; reverse, 5′-TTACATGTAGTGCCACTGCC-3′.
Pbx1b: Forward, 5′-ATGGACGAGCAGCCGAGGC-3′; reverse, 5′-TCACTGTATCCTCCTGTCTGGCTG-3′.
The amplified fragments were digested by EcoRI-XhoI (Meis1a) or BamHI-XhoI (Pbx1b) double digestions and cloned in frame with the GST of pGEX-6p-1 vector (GE Healthcare). All constructs were verified by sequencing them in both directions. GST-Prep1 and GST-fusion proteins production and purification have been described (5). Meis1a and Prep1 were cleaved from GST by PreScission protease. For pull-down assays, 60 μg GST-Pbx1b was bound to 40 μL 50% glutathion-sepharose 4B bead as previously described (5) . Indicated amounts of purified Meis1a and Prep1 were mixed with GST-Pbx1b, which adsorbed to glutathion-sepharose beads. The binding reaction was carried out for 1 h at 4°C in 1 mL buffer of 10 mM Tris·HCl (pH 8), 0.2% Nonidet P-40, and 150 mM NaCl. After thoroughly washing with the buffer, 20 μL 2× Laemli sample buffer was added to each sample, boiled for 5 min, and subjected to 10% (vol/vol) SDS-PAGE followed by Western blotting analysis.
Tandem Affinity Purification and MS Analysis. To construct the Meis1a-tandem affinity purification (TAP) vector, the seamless gene fusion technique by overlap PCR was used (6) . TAP cassette was amplified from the pBabe-Prep1-TAP vector (7) , and the Meis1a fragment was amplified from the cDNA pool from MEFs. Meis1a-TAP fusion fragments were cloned into XhoI/HpaI sites of pMSCVpuro retroviral vector. The following primers were used for cloning.
Meis1a forward primer: 5′-ATGGCGCAAAGGTACGAC-GAC-3′.
Meis1a reverse primer + TAP overlap sequence: 5′-CTTCT-CTTTTCCATTTGCATGTAGTGCCACTGC-3′.
TAP cassette forward primer: 5′-ATGGAAAAGAGAAGAT-GGAAAAAGAATTTC-3′.
TAP cassette reverse primer: 5′-TCAGGTTGACTTCCCC-GCG-3′.
TAP protocol was performed as previously described (7) . The TAP eluates were resolved on 10% (vol/vol) SDS-PAGE. The gel was fixed in 50% (vol/vol) methanol + 10% (vol/vol) acetic acid and stained overnight with the Colloidal Blue staining kit (LC6025; Invitrogen). Different regions were cut out from the gel and trypsinized as previously described (8) . Peptides were desalted (9), dried in a Speed-Vac, and resuspended in 7 μL 0.1% TFA. Liquid chromatography-electrospray ionization-MS/MS of 5 μL each sample was performed on a Fourier-transformed LTQ mass spectrometer (Thermo Electron). Peptides separation was performed on a linear gradient from 100% solvent A [5% (vol/vol) acetonitrile, 0.1% formic acid] to 20% solvent B [99.9% (vol/vol) acetonitrile, 0.1% formic acid] over 20 min and from 20% to 80% solvent B in 5 min at a constant flow rate of 0.3 μL/min on an Agilent chromatographic separation system 1100 (Agilent Technologies). The liquid chromatography system was connected to a 10.5-cm fused silica emitter of 100-μm inner diameter (New Objective, Inc.) and packed in-house with ReproSil-Pur C18-AQ 3-μm beads (Dr. Maisch Gmbh) using a high-pressure bomb loader (Proxeon). Proteins were identified by searching a comprehensive nonredundant protein database (National Center for Biotechnology Information nr) using MASCOT. Nonspecific contaminants (i.e., keratins) were identified after comparison with empty vectorinfected (pMSCV-TAP virus) cells and disregarded. 
